Influence of fluoxetine on the disposition kinetics of dolutegravir among people living with HIV with major depression in nigeria
Active Project Grant Awarded Last action
- Award ID
- K43TW011995
- Recipient
-
College Of Medicine, University Of Ibadan UEI REY7Z9C2K9F9
- Awarding agency
-
Fogarty International Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $260,649
Award facts
- Assistance listing
- 93.242 Mental Health Research Grants
- Completion date 87% complete
- Funding agency
- National Institute of Mental Health National Institutes of Health, Department of Health and Human Services
- Place of performance
- Nigeria
Award details come from USAspending.gov.
Description
- Abstract
- This K43 appplication is being submitted to provide the environment for me to achieve my goal to become an independent physician/scientist investigator and a leader in the study of HIV clinical pharmacology and pharmacogenomics. To continue my progress towards this goal, I have developed a comprehenisive K43 mentored research training program that includes a a longitudinal clincal research project with nested pharmacokinetic drug interaction and pharmacogenomic studies that are based on a hypothesis that combining fluoxetine with dolutegravir-based combination HIV antiviral treatment will increase the plasma concentration of dolutegravir and toxicity. This drug interaction may result in poor medication adherence, suboptimal treatment of depression and inadequate viral suppression. I will investigate this hypothesis during my research project utilizing well-designed pharmacokinetic studies of fluoxetine and dolutegravir in people living with HIV (PLWH) with major depression in nigeria. Depression is a common comorbidity and the most common neuropsychiatric disorder among PLWH. My long-term career research goal is to reduce the morbidity and mortality associated with HIV/aids through the optimization of dosing regimens in PLWH in low-medium income countries. My initial training has allowed me to make progress in developing clinical research skills. However, there are four important areas that I will emphasize during the K43 award period including; (1) design, conduct, monitoring and management of a clinical trial, (2) population pharmacokinetics and pharmacodynamics modeling, (3) pharmacogenomics, and (4) advanced statistical methods. The specific aims of the K43 research plan are: 1. To determine the pharmacologic factors that contribute to the safety and effectiveness of fluoxetine among depressed PLWH treated with dolutegravir-based antiretroviral therapy. 2. To determine the pharmacokinetics of dolutegravir and fluoxetine in adult PLWH with depression. 3. To determine the impact of pharmacogenomics on pharmacokinetics and clinical responses focusing on polymorphisms in metabolizing enzymes and transporters including UGT1A1, SLC22A2, ABCG2, CYP2D6 and CYP3A4. .
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $50,000 | |
| Amendment | $50,000 | |
| Amendment | $21,729 | |
| Amendment | $50,000 | |
| Amendment | $0 | |
| Amendment | $19,460 | |
| Amendment | $50,000 | |
| Original award | $19,460 |
Quick answers
Who received award K43TW011995?
K43TW011995 was awarded to College Of Medicine, University Of Ibadan by Fogarty International Center (National Institutes of Health) on August 2, 2022.
How much is award K43TW011995 worth?
$260,649 has been obligated on K43TW011995.
Which agency awarded K43TW011995?
Fogarty International Center (National Institutes of Health) awarded K43TW011995, with funding from National Institute of Mental Health (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award